TNFRSF9 and cancer: In cancer immunity, effector CD137+T cells have emerged as an optimal immune biomarker for defining the response of (R/M) HNSCC patients to pembrolizumab treatment [34] and for predicting the clinical outcome of patients receiving cancer treatments [35, 36].